Header Logo

Connection

KIM-ANH DO to Survival Analysis

Back to Details
This is a "connection" page, showing publications KIM-ANH DO has written about Survival Analysis.
KIM-ANH DO
Connection Strength
0.237
Survival Analysis
  1. Integrative network-based Bayesian analysis of diverse genomics data. BMC Bioinformatics. 2013; 14 Suppl 13:S8.
    View in: PubMed
    Score: 0.052
  2. Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics. 2011 Feb 01; 27(3):359-67.
    View in: PubMed
    Score: 0.043
  3. A Bayesian semiparametric survival model with longitudinal markers. Biometrics. 2010 Jun; 66(2):435-43.
    View in: PubMed
    Score: 0.038
  4. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
    View in: PubMed
    Score: 0.014
  5. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One. 2014; 9(9):e108635.
    View in: PubMed
    Score: 0.014
  6. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
    View in: PubMed
    Score: 0.009
  7. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
    View in: PubMed
    Score: 0.009
  8. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
    View in: PubMed
    Score: 0.008
  9. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
    View in: PubMed
    Score: 0.008
  10. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
    View in: PubMed
    Score: 0.007
  11. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004 Oct 15; 10(20):6770-8.
    View in: PubMed
    Score: 0.007
  12. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 01; 101(7):2507-13.
    View in: PubMed
    Score: 0.006
  13. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
    View in: PubMed
    Score: 0.006
  14. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002 May; 235(5):722-30; discussion 730-1.
    View in: PubMed
    Score: 0.006
  15. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan; 13(1):125-34.
    View in: PubMed
    Score: 0.006
  16. Reconstructive management of cranial base defects after tumor ablation. Plast Reconstr Surg. 2001 May; 107(6):1346-55; discussion 1356-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.